Latest News
Opinion: STAT+: The FDA’s absence from international standards meetings threatens U.S. leadership
U.S. leadership in drugs, biologics, and devices is now at risk.
STAT+: Eli Lilly says it will hike list prices for drugs abroad. Now what?
And more biotech news of the day, brought to you by The Readout.
Opinion: The CDC shooting was public health’s Jan. 6
“In RFK Jr.’s America, it will never be safe to practice public health or medicine," write an epidemiologist and a former CDC staffer.
Draft of major MAHA report calls for more education, less regulation — and offers few policies
A draft of RFK Jr.'s much-awaited strategy for a healthier America softens rhetoric on agricultural chemicals and stresses education on food and fitne...
STAT+: Novo Nordisk’s obesity drug Wegovy cleared to treat MASH
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.
STAT+: Pharmalittle: We’re reading about Trump and tariffs, a new pharma lobbying group, and much more
A handful of drug companies have formed a group to present lawmakers with research on the negative impacts of Medicare drug price negotiations
How clinicians write about Black patients in the EHR
And more health news stories of the day.
STAT+: U.S. warning on use of ‘march-in’ rights against Harvard seems like distant threat for pharma
A recent U.S. warning on use of 'march-in' rights against Harvard University seems like distant threat for pharma. Here's why.
STAT+: In a financial fix, Sarepta sells Arrowhead stock
Plus more biotech news stories of the day, brought to you by The Readout.
STAT+: Modified antibody shows promise for treating metastatic cancer, early trial shows
A modified CD40 antibody shrank or eliminated tumors in six of 12 metastatic cancer patients without the side effects that plagued earlier CD40 studie...
Opinion: STAT+: The FDA’s absence from international standards meetings threatens U.S. leadership
STAT+: Eli Lilly says it will hike list prices for drugs abroad. Now what?
Opinion: The CDC shooting was public health’s Jan. 6
Draft of major MAHA report calls for more education, less regulation — and offers few policies
STAT+: Novo Nordisk’s obesity drug Wegovy cleared to treat MASH
STAT+: Pharmalittle: We’re reading about Trump and tariffs, a new pharma lobbying group, and much more
How clinicians write about Black patients in the EHR
STAT+: U.S. warning on use of ‘march-in’ rights against Harvard seems like distant threat for pharma
STAT+: In a financial fix, Sarepta sells Arrowhead stock
STAT+: Modified antibody shows promise for treating metastatic cancer, early trial shows
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago